HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced the appointment of Kristen M. Hege, M.D., to its Board of
Directors. Dr. Hege brings more than 20 years of oncology clinical
leadership experience to Arcus’s board.
“We are thrilled to welcome Dr. Hege to our Board of Directors,” said
Terry Rosen, Ph.D., Chief Executive Officer at Arcus. “Dr. Hege brings
extensive and highly relevant experience in translational medicine and
clinical development in oncology to Arcus and has the ideal background
to contribute to our Company’s biomarker strategy and clinical
development plans. Also, as Dr. Hege has served as a member of our
Scientific Advisory Board and as a Board Observer, she is already very
familiar with Arcus and knowledgeable on the pathways we are
pursuing. We look forward to having access to Dr. Hege’s extraordinary
experience, perspectives and wisdom as we expand our clinical
development programs and explore opportunities to bring our medicines to
cancer patients as rapidly as possible.”
Dr. Hege currently serves as Corporate Vice President, Translational
Development, Hematology and Oncology and San Francisco site head at
Celgene where she is responsible for translational and early clinical
development for all hematology and oncology products including small
molecules, biologics and cell therapies. Prior to joining Celgene, she
served as acting Chief Medical Officer at Aragon Pharmaceuticals,
Theraclone Sciences and Cellerant Therapeutics. Dr. Hege began her
career at Cell Genesys Inc. where she spent 14 years in various roles of
increasing responsibility, ultimately leading the Clinical Research and
Development organization.
Dr. Hege is currently a Clinical Professor of Medicine, Hematology and
Oncology and an attending physician at the University of California, San
Francisco (UCSF). She has held a clinical faculty appointment at UCSF
since 1997 in the adult hematology and bone marrow transplant program.
Dr. Hege has been board-certified in internal medicine, medical oncology
and hematology. Dr. Hege received her B.A. summa cum laude from
Dartmouth, M.D. from UCSF, and completed a medical residency at Brigham
& Women's Hospital, Harvard Medical School and a fellowship in
hematology and oncology at UCSF. She serves on the Board of Directors of
the Society for Immunotherapy of Cancer and Mersana Therapeutics and the
Strategic Advisory Group for the Parker Institute for Cancer
Immunotherapy. In 2015, FierceBiotech recognized her as one of the top
12 women in Biopharma.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist AB928, which is in a Phase 1/1b program to
evaluate AB928 in combination with other agents in multiple tumor types,
and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1
trial and is being tested in combination with Arcus’s other product
candidates. Arcus’s other programs include AB154, an anti-TIGIT
antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy
and in combination with AB122, and AB680, a small molecule inhibitor of
CD73, which is in IND-enabling studies. Arcus has extensive in-house
expertise in medicinal chemistry, immunology, biochemistry, pharmacology
and structural biology. For more information about Arcus Biosciences,
please visit www.arcusbio.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein, including,
but not limited to, the scope and pace of Arcus’s clinical development
efforts, are forward-looking statements reflecting the current beliefs
and expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause Arcus’s actual
results, performance or achievements to differ significantly from those
expressed or implied. Factors that could cause or contribute to such
differences include, but are not limited to, the inherent uncertainty
associated with pharmaceutical product development and clinical trials,
including unexpected safety data observed during our clinical trials,
changes in expected or existing competition, difficulties or delays in
the initiation and enrollment of our clinical trials and changes in the
regulatory environment. Risks and uncertainties facing Arcus are
described more fully in Arcus’s quarterly report on Form 10-Q for the
quarter ended June 30, 2018 filed on August 6, 2018 with the SEC. You
are cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date of this press release. Arcus
disclaims any obligation or undertaking to update, supplement or revise
any forward-looking statements contained in this press release.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181022005262/en/
Arcus Biosciences, Inc.
Jennifer Jarrett, 510-694-6261
jjarrett@arcusbio.com
Or
Nicole
Arndt, 510-284-4728
narndt@arcusbio.com
Source: Arcus Biosciences